204 related articles for article (PubMed ID: 26198556)
1. Natriuretic Peptides and the Management of Heart Failure.
Kern T; Kedan I; Kimchi A
Rev Cardiovasc Med; 2015; 16(2):95-104. PubMed ID: 26198556
[TBL] [Abstract][Full Text] [Related]
2. Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?
Logan JK; Mentz RJ
Curr Heart Fail Rep; 2019 Dec; 16(6):250-256. PubMed ID: 31741230
[TBL] [Abstract][Full Text] [Related]
3. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
[TBL] [Abstract][Full Text] [Related]
4. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
[TBL] [Abstract][Full Text] [Related]
5. Natriuretic peptide and cardiovascular risk: is it about "U"?
deFilippi CR; Seliger SL
J Am Heart Assoc; 2015 May; 4(5):. PubMed ID: 25999399
[No Abstract] [Full Text] [Related]
6. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
[TBL] [Abstract][Full Text] [Related]
7. A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure.
Francis GS; Felker GM; Tang WH
J Am Coll Cardiol; 2016 Jan; 67(3):330-7. PubMed ID: 26796399
[TBL] [Abstract][Full Text] [Related]
8. Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients - Multiple biomarkers prospective cohort study.
Parenica J; Kala P; Pavkova MG; Tomandl J; Spinar J; Littnerova S; Jarkovsky J; Mebazaa A; Tomandlova M; Dastych M; Gottwaldova J; Gayat E
Int J Cardiol; 2016 May; 211():96-104. PubMed ID: 26991556
[TBL] [Abstract][Full Text] [Related]
9. [A national campaign for the promotion of the appropriate use of natriuretic peptide assays in heart failure patients].
Di Lenarda A
G Ital Cardiol (Rome); 2016 Jan; 17(1):48-50. PubMed ID: 26901258
[No Abstract] [Full Text] [Related]
10. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.
Motiwala SR; Januzzi JL
Clin Pharmacol Ther; 2013 Jan; 93(1):57-67. PubMed ID: 23187878
[TBL] [Abstract][Full Text] [Related]
11. Natriuretic peptides as biomarkers in heart failure.
Januzzi JL
J Investig Med; 2013 Aug; 61(6):950-5. PubMed ID: 23661103
[TBL] [Abstract][Full Text] [Related]
12. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction.
Gruson D; Lepoutre T; Ahn SA; Rousseau MF
Int J Cardiol; 2014; 172(1):e250-2. PubMed ID: 24467978
[No Abstract] [Full Text] [Related]
13. Natriuretic Peptides in Clinical Practice.
Çavuşoğlu Y; Alper AT; Altay H; Çelik A; Demirkan B; Güvenç TS; Küçükoğlu MS; Nalbantgil S; Özdemir M; Özin B; Sayın T; Yıldırımtürk Ö; Yılmaz MB; Zorkun C
Anatol J Cardiol; 2019 Mar; 21(Suppl 1):1-40. PubMed ID: 30860204
[TBL] [Abstract][Full Text] [Related]
14. Evolution of natriuretic peptides testing in heart failure - Impact of novel therapies.
Mitoff P
Clin Biochem; 2016 Jun; 49(9):643-644. PubMed ID: 27060498
[No Abstract] [Full Text] [Related]
15. Natriuretic peptides in the diagnosis and management of chronic heart failure.
Boerrigter G; Costello-Boerrigter LC; Burnett JC
Heart Fail Clin; 2009 Oct; 5(4):501-14. PubMed ID: 19631175
[TBL] [Abstract][Full Text] [Related]
16. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
Green SM; Green JA; Januzzi JL
Am J Ther; 2009; 16(2):171-7. PubMed ID: 19300043
[TBL] [Abstract][Full Text] [Related]
17. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
[TBL] [Abstract][Full Text] [Related]
18. Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials.
Vodovar N; Mebazaa A; Januzzi JL; Murtagh G; Stough WG; Adams KF; Zannad F
Int J Cardiol; 2018 Mar; 254():215-221. PubMed ID: 29407093
[TBL] [Abstract][Full Text] [Related]
19. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.
Wessler BS; Kramer DG; Kelly JL; Trikalinos TA; Kent DM; Konstam MA; Udelson JE
Circ Heart Fail; 2011 Sep; 4(5):578-88. PubMed ID: 21705485
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
